ZENITHDRUG

Zenith Drugs Share Price

 

 

Start SIP in ZENITHDRUG

Start SIP

Performance

  • Low
  • ₹58
  • High
  • ₹60
  • 52 Week Low
  • ₹47
  • 52 Week High
  • ₹107
  • Open Price₹58
  • Previous Close₹60
  • Volume10,400

Investment Returns

  • Over 1 Month -2.47%
  • Over 3 Month -7.78%
  • Over 6 Month -25.41%
  • Over 1 Year -40.13%

Smart Investing Starts Here Start SIP with Zenith Drugs for Steady Growth!

Invest Now

Zenith Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.2
  • PEG Ratio
  • -
  • Market Cap Cr
  • 102
  • P/B Ratio
  • 1.6
  • Average True Range
  • 3.16
  • EPS
  • 4.26
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.11
  • RSI
  • 41.72
  • MFI
  • 46.85

Zenith Drugs Financials

Zenith Drugs Technicals

EMA & SMA

Current Price
₹59.30
-0.9 (-1.5%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹62.15
  • 50 Day
  • ₹64.38
  • 100 Day
  • ₹67.28
  • 200 Day
  • ₹71.32

Resistance and Support

59.25 Pivot Speed
  • R3 62.95
  • R2 61.70
  • R1 60.50
  • S1 58.05
  • S2 56.80
  • S3 55.60

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Zenith Drugs Ltd has an operating revenue of Rs. 334.35 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 7% is okay, ROE of 10% is good. The company has a reasonable debt to equity of 18%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 42 which is a POOR score indicating inconsistency in earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Zenith Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-29 Audited Results & Others To consider Other business matters. Final Dividend of Re. 0.5 per equity share
2025-04-17 To consider Fund Raising & Others To consider Other business matters. (Revised) Final Dividend of Re. 0.5 per equity share
2024-11-14 Quarterly Results
2024-05-29 Audited Results
Date Purpose Remarks
2024-09-18 FINAL Re.0.00 Final Dividend of Re. 0.5 per equity share
View Zenith Drugs Dividend History Arrow

Zenith Drugs F&O

Zenith Drugs Shareholding Pattern

69.98%
0%
25.26%
4.76%

About Zenith Drugs

  • NSE Symbol
  • ZENITHDRUG
  • BSE Symbol
  • Managing Director
  • Mr. Sandeep Bhardwaj
  • ISIN
  • INE0QWN01013

Similar Stocks to Zenith Drugs

Zenith Drugs FAQs

Zenith Drugs share price is ₹59 As on 15 November, 2025 | 15:03

The Market Cap of Zenith Drugs is ₹101.7 Cr As on 15 November, 2025 | 15:03

The P/E ratio of Zenith Drugs is 14.2 As on 15 November, 2025 | 15:03

The PB ratio of Zenith Drugs is 1.6 As on 15 November, 2025 | 15:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23